<DOC>
	<DOCNO>NCT00427245</DOCNO>
	<brief_summary>RATIONALE : Goserelin may help prevent early menopause patient undergo chemotherapy breast cancer . It yet know whether goserelin effective prevent early menopause woman undergo chemotherapy breast cancer . PURPOSE : This randomized phase III trial study goserelin see well work compare goserelin prevent early menopause premenopausal woman undergo chemotherapy stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Goserelin Preventing Early Menopause Premenopausal Women Undergoing Chemotherapy Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare incidence premature ovarian failure chemotherapy premenopausal woman stage I-III breast cancer treat goserelin v goserelin . Secondary - Compare quality life patient treat regimen . - Compare menopausal symptoms patient treated regimen . - Compare bone mineral density loss patient treat regimen . - Compare hormone level patient treat regimen . - Compare menstruation patient treat regimen . - Compare incidence pregnancy patient treat regimen . OUTLINE : This randomize , open-label , prospective , parallel group , multicenter study . Patients stratify accord age ( â‰¤ 40 year vs &gt; 40 year ) participate center . Patients randomize 1 2 treatment arm . Arm I ( chemotherapy alone ) : Patients receive neoadjuvant adjuvant cyclophosphamide- and/or anthracycline-containing chemotherapy . Treatment continue 6-8 course absence disease progression unacceptable toxicity . Arm II ( chemotherapy plus goserelin ovarian function suppression ) : Patients receive neoadjuvant adjuvant chemotherapy arm I . Patients also receive goserelin subcutaneously every 3-4 week begin 1-3 week start chemotherapy . Treatment goserelin repeat every 3-4 week completion chemotherapy . Quality life assess baseline , 3 , 6 , 12 , 18 , 24 month , annually 5 year . After completion study therapy , patient follow periodically 5 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Stages IIIIB nodepositive negative disease ( N02 ) Operable disease Must meet 1 follow criterion : Has undergone mastectomy breastconserving surgery complete excision primary tumor within past 8 week Scheduled receive neoadjuvant chemotherapy No metastatic breast cancer , include supraclavicular fossa metastases Hormone receptor status meet 1 follow criterion : Estrogen receptor ( ER ) progesterone receptor poor negative AND candidate adjuvant endocrine therapy ER positive AND requirement ovarian suppression necessary part treatment PATIENT CHARACTERISTICS : Female Premenopausal regular menses 12 month precede surgery No prior concurrent invasive malignancy except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Suitable fitness status chemotherapy Adequate hepatic , renal , bone marrow function Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy endocrine therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>menopausal symptom</keyword>
	<keyword>infertility</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
</DOC>